Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurocrine BiosciencesFRA:NB3 -2.56%94 Net Current Asset Value is €8.06 as of Mar. 2026, which is 100% below its 10-year median of 22.06. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €165.56 (Fairly Valued). The stock has 6 warning signs investors should review. Among 611 Drug Manufacturers companies, Neurocrine Biosciences ranks worse than 82.16% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Neurocrine Biosciences's net current asset value per share for the quarter that ended in Mar. 2026 was €8.06.
The historical rank and industry rank for Neurocrine Biosciences's Net Current Asset Value or its related term are showing as below:
FRA:NB3'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 10.99 Med: 22.06 Max: 103.66
Current: 18.67
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Neurocrine Biosciences was 103.66. The lowest was 10.99. And the median was 22.06.
FRA:NB3's Price-to-Net-Current-Asset-Value is ranked worse than 82.16% of 611
companies
in the Drug Manufacturers industry
Industry Median: 5.72
vs FRA:NB3: 18.67
Neurocrine Biosciences (FRA:NB3) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Neurocrine Biosciences Net Current Asset Value Related Terms
Neurocrine Biosciences Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Neurocrine Biosciences's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Neurocrine Biosciences Net Current Asset Value Chart
FRA:NB3 vs VTRS, ELAN, UTHR: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neurocrine Biosciences's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurocrine Biosciences Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurocrine Biosciences's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Neurocrine Biosciences's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €8.06 mean?
Neurocrine Biosciences (FRA:NB3) has a Net Current Asset Value of €8.06 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Neurocrine Biosciences and its competitors. This is 63% below median its historical median of 22.06. Over the past decade, Neurocrine Biosciences' Net Current Asset Value has ranged from 10.99 to 103.66. According to the industry distribution chart, Neurocrine Biosciences ranks #502 out of 611 companies in the Drug Manufacturers industry, placing it in the top 82.2%.
Is Neurocrine Biosciences' Net Current Asset Value too high?
Neurocrine Biosciences' current Net Current Asset Value of €8.06 is 63% below median its 10-year median of 22.06. Over the past 10 years, this metric has ranged from a low of 10.99 to a high of 103.66. Based on the distribution chart, Neurocrine Biosciences ranks #502 out of 611 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Net Current Asset Value compare to VTRS and ELAN?
According to the Drug Manufacturers industry distribution chart, Neurocrine Biosciences ranks #502 out of 611 companies for Net Current Asset Value. This places Neurocrine Biosciences in the lower half of its industry. The industry median Net Current Asset Value is 5.72. Historically, Neurocrine Biosciences' own Net Current Asset Value has ranged from 10.99 to 103.66 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.72, based on 611 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Neurocrine Biosciences and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.72 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurocrine Biosciences's current Net Current Asset Value is €8.06, which is 63% below median its own 10-year median of 22.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €165.56, compared to a current price of €152.20 — trading 8.1% below its estimated fair value. The current Net Current Asset Value is €8.06, which is 63% below median its 10-year median of 22.06. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Net Current Asset Value is €8.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?
Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued.
The current stock price of €152.20 is trading 8.1% below its estimated GF Value™ of €165.56.
GuruFocus considers Neurocrine Biosciences to be Fairly Valued.
Key valuation signals for FRA:NB3:
Net Current Asset Value: €8.06 (63% below median its 10-year median of 22.06)
GF Value™: €165.56 vs. price of €152.20 (8.1% below fair value)
No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score
Get the complete analysis for FRA:NB3
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:NB3 has been successfully added to your 
